A family embarked on an unprecedented journey to develop a gene therapy for their son Riaan, who was diagnosed with the ultra-rare genetic disorder Cockayne syndrome at 15 months old. The condition causes progressive disease and early death, with Riaan's life expectancy initially estimated at five years.
Cockayne syndrome affects DNA repair and cellular health. The experimental gene therapy aimed to introduce a healthy copy of the affected gene, CSA, into Riaan's brain, hoping to restore protein production and halt the disease's progression. Riaan, now 6, was born small, developed cataracts as an infant, and missed developmental milestones, struggling with feeding and growth. His small stature persists, as he still fits into clothing meant for an 18-month-old.
Motivated by love and the urgency of their son's diagnosis, the parents launched the Riaan Research Initiative. Through advocacy and fundraising, they raised $4 million to advance the therapy from concept to clinical application. The process involved years of intensive work, navigating scientific, clinical, manufacturing, and regulatory challenges. A critical phase was the 30-day review period for their Investigational New Drug application with the U.S. Food and Drug Administration, where incorrect responses could lead to a clinical hold.
Despite successfully bringing the therapy to the brink of administration, the parents faced a profound ethical dilemma. Riaan had advanced disease, yet he was stable and had never been hospitalized. They debated the risks of the procedure—including brain surgery, a hospital stay, immunosuppression, and the unknown consequences of a first-in-human therapy—against the potential for a longer, healthier life. Gene therapy carries risks, including liver failure and inflammatory responses, and the necessary immunosuppression is also a significant concern.
This therapy offered the only hope, and if successful, could provide a proof of concept for treating other children with Cockayne syndrome. While neonatal mouse models showed extended lifespan and improved quality of life, the leap to a human child presented uncertainties. The parents grappled with the burden of this decision, particularly as Riaan, being non-verbal, could not consent for himself.
Seeking guidance, they spoke with families who had navigated similar paths, and all advised proceeding. A sign from Riaan, who touched his mother's nose when asked if he wanted the therapy, also played a role in their decision. Support from scientists and physicians at UMass Chan Medical School and Weill Cornell, along with a trusted physician-scientist advisor, bolstered their confidence.
Ultimately, they decided to proceed. The day of the procedure on April 21, 2026, was fraught with emotion. After Riaan was anesthetized, he was administered the gene therapy. The post-procedure recovery was intense, with Riaan experiencing significant distress, but he gradually improved. He was monitored closely following his discharge from the hospital.
It will take months or years to determine the therapy's long-term benefits. Riaan remains clinically stable, showing encouraging changes and his usual joyful demeanor. The family has manufactured enough drug for multiple children and plans to work with the FDA to gain approval for wider use, while also seeking funds to cover clinical costs.
The parents emphasized that families of children with rare diseases should not have to become drug developers out of necessity. They view their efforts as a testament to their love for Riaan, stating they would undertake the process again for him and for future children who may benefit.
